Consolidated Statement Of Cash Flows

Astellas Pharma Inc. - Filing #7604918

Concept 2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
As at
2022-03-31
2021-04-01 to
2022-03-31
2021-04-01 to
2022-03-31
As at
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
As at
2020-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
JPY
JPY
JPY
JPY
124,086,000,000 JPY
JPY
124,086,000,000 JPY
JPY
124,086,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
120,589,000,000 JPY
JPY
120,589,000,000 JPY
JPY
120,589,000,000 JPY
JPY
Impairment losses (reversal of impairment losses)
74,850,000,000 JPY
100,348,000,000 JPY
Decrease (increase) in inventories
24,058,000,000 JPY
-2,318,000,000 JPY
Other
-16,639,000,000 JPY
47,389,000,000 JPY
Subtotal
299,537,000,000 JPY
324,714,000,000 JPY
Income taxes paid
-42,093,000,000 JPY
-17,870,000,000 JPY
Net cash provided by (used in) operating activities
257,444,000,000 JPY
306,843,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-30,739,000,000 JPY
-31,384,000,000 JPY
Proceeds from sale of property, plant and equipment
441,000,000 JPY
6,831,000,000 JPY
Purchase of intangible assets
-45,709,000,000 JPY
-46,057,000,000 JPY
Payments for acquisition of subsidiaries
-670,000,000 JPY
-14,916,000,000 JPY
Other
-10,733,000,000 JPY
2,594,000,000 JPY
Net cash provided by (used in) investing activities
-62,413,000,000 JPY
-81,894,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
80,000,000,000 JPY
Repayments of long-term borrowings
-30,000,000,000 JPY
JPY
Purchase of treasury shares
-50,717,000,000 JPY
-9,163,000,000 JPY
Other
-2,530,000,000 JPY
-2,268,000,000 JPY
Net cash provided by (used in) financing activities
-216,298,000,000 JPY
-229,479,000,000 JPY
Cash and cash equivalents
315,986,000,000 JPY
326,128,000,000 JPY
318,391,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
11,125,000,000 JPY
12,267,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.